Image The vaccines landscape is very different now as compared to few years back. With increasing public awareness about preventive healthcare and increased spending by governments for the same has once again put spotlight on the vaccines.

Quality of life is expected to increase markedly with introduction of newer vaccines covering more and more diseases. Due to this vaccines, which were perceived as low margin business before, have now emerged as one of the most lucrative segments in the pharmaceutical industry. Moreover with the success of a number of blockbuster products, the market place has changed dramatically. Pharma major's today look upon vaccines as a driver for their future growth.

Already vaccines have become big business for pharmaceutical giants like GlaxoSmithKline, sanofi pasteur and Merck & Co. For e.g. GSK Bio, GSK's vaccines arm, accounted for 8.4 percent of GSK's pharmaceutical turnover in 2006. And it is expected that by 2012 companies like GSK, Sanofi-aventis, Merck & Co., and Wyeth vaccines arm will fetch them more than 10 percent of sales from vaccine as a percentage of overall pharma sales.

Sector wise basic pediatrics share is declining as most of the vaccines in this sector are either off patent or newer and more effective vaccines have replaced them. Proprietary pediatrics and cancer pediatrics will define the future growth going forward. Vaccines like Prevnar (Pneumococcal vaccines), Gardasil (Cervical cancer vaccines) have crossed the sales of US$ 1 Billion by 2007. In fact Prevnar became the first vaccine to cross the US$ 2 Billion annual sales in 2007.

With the growth in international travel vaccine market of adult/travel sector is also going to grow further. Malaria vaccines, Typhoid Vaccines and Japanese Encephalitis Vaccines are expected to grow further in the market. Malaria vaccine which is expected to launch in 2010 or 2011, is forecasted to be worth US$ 419 Million market by 2025. Typhoid vaccine market for travelers is expected to grow with a CAGR of 4 percent from 2003 to 2014.

Ongoing spate of mergers and acquisition in pharma sector its effect and causes on the overall industry. Such as Pfizer taking over Wyeth would cement Pfizer's position as the world's leading drugmaker. Geographic segment wise China and India vaccine market will grow considerably in future and Japanese vaccine market has also started to open up further from regulatory and political barriers. Overall the worldwide vaccine market has registered revenue of US$ 21 Billion in 2008.